Want to join the conversation?
Biopharma company $LGND has initiated a Phase 2 clinical trial with its glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM). This study will evaluate the safety and efficacy of LGD-6972 in patients with T2DM whose blood glucose levels are inadequately controlled with metformin.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.